Our results show growth inhibition by DCA on three ccRCC cell lines, suggesting that poor prognosis-PDK2/PDK3 high expression ccRCC cases could benefit upon treatment with DCA analogues. This evidence concerns the gene PDK3 and nonpapillary renal cell carcinoma.